We are live on ! Find out more
TVRD

Tvardi Therapeutics
TVRD

56 hedge funds and large institutions have $44.9M invested in Tvardi Therapeutics in 2025 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 15 increasing their positions, 8 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,298% more capital invested

Capital invested by funds: $3.21M → $44.9M (+$41.7M)

767% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 3

88% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 8

70% more funds holding

Funds holding: 33 → 56 (+23)

16.16% more ownership

Funds ownership: 4.62% → 20.78% (+16%)

Holders
56
Holders Change
+23
Holders Change %
+69.7%
% of All Funds
0.74%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
15
Reduced
8
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SPC
Slate Path Capital
New York
+$16.6M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$8.1M
3
BlackRock
BlackRock
New York
+$5.85M
4
6CM
683 Capital Management
New York
+$4.16M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.34M

Top Sellers

Rank Fund Capital Flow
1
Two Sigma Advisers
Two Sigma Advisers
New York
-$249K
2
Millennium Management
Millennium Management
New York
-$88.3K
3
LPL Financial
LPL Financial
California
-$61.6K
4
FCM
Farallon Capital Management
California
-$71
5
Osaic Holdings
Osaic Holdings
Arizona
-$71
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
26
Ameritas Investment Partners
Nebraska
$8.14K +$8.25K +349 New
Legal & General Group
27
Legal & General Group
United Kingdom
$7.23K +$7.33K +310 New
BNP Paribas Financial Markets
28
BNP Paribas Financial Markets
France
$7K +$6.81K +288 +2,400%
Royal Bank of Canada
29
Royal Bank of Canada
Ontario, Canada
$6K +$5.98K +253 +1,946%
California State Teachers Retirement System (CalSTRS)
30
California State Teachers Retirement System (CalSTRS)
California
$4.97K +$5.04K +213 New
AB
31
Amalgamated Bank
New York
$3K +$2.77K +117 New
TRCT
32
Tower Research Capital (TRC)
New York
$2.4K +$2.44K +103 New
LI
33
LRI Investments
Florida
$1.91K -$24 -1 -1%
SCM
34
Sterling Capital Management
North Carolina
$1.91K +$1.94K +82 New
Raymond James Financial
35
Raymond James Financial
Florida
$1.52K +$1.54K +65 New
Osaic Holdings
36
Osaic Holdings
Arizona
$954 -$71 -3 -7%
Jones Financial Companies
37
Jones Financial Companies
Missouri
$591 +$213 +9 +60%
ME
38
McIlrath & Eck
Washington
$467 – – –
AF
39
Allworth Financial
California
$444 +$307 +13 +217%
Group One Trading
40
Group One Trading
Illinois
$327 – – –
HI
41
Harbour Investments
Wisconsin
$327 – – –
KWM
42
Kiker Wealth Management
Georgia
$303 -$47 -2 -13%
LSA
43
Leonteq Securities AG
Switzerland
$280 +$284 +12 New
MCM
44
MAI Capital Management
Ohio
$234 – – –
TCOT
45
Trust Company of Toledo
Ohio
$210 +$213 +9 New
PPA
46
Painted Porch Advisors
California
$140 -$24 -1 -14%
CFD
47
Creative Financial Designs
Indiana
$140 – – –
Fidelity Investments
48
Fidelity Investments
Massachusetts
$117 +$95 +4 +400%
SS
49
SBI Securities
Japan
$93 -$47 -2 -33%
TC
50
Truvestments Capital
Florida
$93 +$95 +4 New
1
2
3

TVRD Hedge Fund Activity: Q2 2025 in Review

56 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q2 2025, worth a combined $44.9M — up 1,298% from $3.21M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new TVRD positions and 3 closed out — a net gain of 23 holders — while 15 added to existing stakes and 8 trimmed.

The largest buyer was Slate Path Capital, opening a new position worth an estimated $16.6M. The largest seller was Two Sigma Advisers, exiting entirely with an estimated $249K sold.

  • 56 institutional investors held Tvardi Therapeutics (TVRD) as of Q2 2025, up from 33 in Q1 2025.
  • Funds reported $44.9M of Tvardi Therapeutics stock for Q2 2025, up 1,298% quarter-over-quarter.
  • 26 funds opened new Tvardi Therapeutics positions in Q2 2025 and 3 closed out, a net change of +23 holders.
  • The largest Tvardi Therapeutics buyer in Q2 2025 was Slate Path Capital, an estimated $16.6M added.
  • The largest Tvardi Therapeutics seller in Q2 2025 was Two Sigma Advisers, an estimated $249K sold.

Based on aggregated 13F filings for Q2 2025.